Search

Search Constraints

You searched for: Author/Creator Joyce, Daniel D.

Search Results

1. Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data. Issue 24 (17th October 2022)

2. Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov Model. Issue 1 (6th January 2023)

3. Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). Issue 6 (10th December 2021)

5. MP27-19 COMPARATIVE OUT-OF-POCKET COSTS OF TREATMENT OPTIONS IN PRIVATELY INSURED PATIENTS WITH ADVANCED PROSTATE CANCER. (May 2022)

6. MP39-13 COST-EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY REGIMENS PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER. (May 2022)

7. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients. Issue 5 (12th November 2022)

9. PD56-03 CONTEMPORARY PERIOPERATIVE COMPLICATIONS OF SURGERY FOR RENAL CELL CARCINOMA WITH INFERIOR VENA CAVA THROMBECTOMY. (1st May 2022)

10. PD59-05 COST EFFECTIVENESS OF ADJUVANT PEMBROLIZUMAB AFTER NEPHRECTOMY FOR RCC: INSIGHTS FOR PATIENT SELECTION FROM A MARKOV MODEL. (May 2022)